Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PUVA is a combination treatment that consists of psoralen (a light-sensitive drug) and ultraviolet A (UVA) light exposure. Psoralens are compounds found in many plants that make the skin temporarily sensitive to UVA light. When activated by UVA radiation, psoralens interact with DNA to slow down cell multiplication, which helps treat various skin conditions. The treatment can be administered in several ways: oral psoralen taken 1.5-2 hours before UVA exposure, bathwater PUVA where the patient soaks in a psoralen solution, or topical PUVA where psoralen is applied directly to the skin before UVA exposure. PUVA treatment is typically given 2-3 times per week for 12-15 weeks, with exposure times gradually increasing based on patient response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on psoralen + ultraviolet A.